Low Molecular Weight Heparin vs Direct Oral Anticoagulant After Bariatric Surgery

Cairo University (CU)

Status and phase: Active, not recruiting; Phase 1

Conditions: Deep Venous Thrombosis

Treatments: Drug: Direct Oral Anticoagulant.; Drug: Low Molecular Weight Heparine

Study type: Interventional

Funder types: Other

Identifiers

NCT06913595

N-55-2024

Details and patient eligibility

About

Extended Venous Thromboemboism Prophylaxis After Bariatric Surgeries: A Comparison Of Low Molecular Weight Heparin With Direct Oral Anticoagulant

Full description

This study aims to compare the effectiveness of rivaroxaban versus low molecular weight heparin in reducing the incidence of PMVT after bariatric surgery.

Enrollment: 100 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

- BARIATRIC PATIENTS

Exclusion criteria

• BLEEDING TENDENCY

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

100 participants in 2 patient groups

Low Molecular Weight Heparin

Active Comparator group

Description:

Low molecular weight heparin as aprophylaxis after bariatric surgery

Treatment:

Drug: Low Molecular Weight Heparine

Direct Oral Anticoagulant.

Experimental group

Description:

Direct Oral Anticoagulant as aprophylaxis after bariatric surgery

Treatment:

Drug: Direct Oral Anticoagulant.